Chronic GVHD: Onset and Manifestations
| Acute GVHD | |
| 0 | 3 (14%) |
| I | 7 (32%) |
| II-IV | 12 (56%) |
| Onset cGVHD | |
| Quiescent | 16 (73%) |
| Progressive | 3 (14%) |
| De novo | 3 (14%) |
| Median day to onset of cGVHD after BMT/T-cell infusion (range) | 173 days (23-585 days) |
| Limited/extensive | 6/16 |
| Median hematologic parameters (range) at onset of cGVHD | |
| Platelets | 152,000/μL (69,000- |
| 413,000/μL) | |
| WBC | 6.8/μL (2.7-54/μL) |
| Immunosuppressive medications at start of clofazimine | |
| Steroids + cyclosporine | 17 (77%) |
| Steroids alone | 2 (9%) |
| Cyclosporine alone | 1 (5%) |
| None | 2 (9%) |
| Immunosuppressive medications at end of clofazimine | |
| Steroids + cyclosporine | 12 (55%) |
| Steroids alone | 4 (18%) |
| Cyclosporine alone | 1 (5%) |
| None | 5 (23%) |
| Median Karnofsky performance status (range) | 70 (40-90) |
| Mean length of clofazimine course (range)* | 313 days (7-835 days) |
| Acute GVHD | |
| 0 | 3 (14%) |
| I | 7 (32%) |
| II-IV | 12 (56%) |
| Onset cGVHD | |
| Quiescent | 16 (73%) |
| Progressive | 3 (14%) |
| De novo | 3 (14%) |
| Median day to onset of cGVHD after BMT/T-cell infusion (range) | 173 days (23-585 days) |
| Limited/extensive | 6/16 |
| Median hematologic parameters (range) at onset of cGVHD | |
| Platelets | 152,000/μL (69,000- |
| 413,000/μL) | |
| WBC | 6.8/μL (2.7-54/μL) |
| Immunosuppressive medications at start of clofazimine | |
| Steroids + cyclosporine | 17 (77%) |
| Steroids alone | 2 (9%) |
| Cyclosporine alone | 1 (5%) |
| None | 2 (9%) |
| Immunosuppressive medications at end of clofazimine | |
| Steroids + cyclosporine | 12 (55%) |
| Steroids alone | 4 (18%) |
| Cyclosporine alone | 1 (5%) |
| None | 5 (23%) |
| Median Karnofsky performance status (range) | 70 (40-90) |
| Mean length of clofazimine course (range)* | 313 days (7-835 days) |
Abbreviation: BMT, bone marrow transplant.
One patient received three courses (983 days total) and one patient received two courses (295 days total). Six patients remain on therapy.